Veracity Capital LLC Sells 21,406 Shares of Fresenius Medical Care AG & Co. KGaA $FMS

Veracity Capital LLC lowered its position in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 59.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 14,684 shares of the company’s stock after selling 21,406 shares during the period. Veracity Capital LLC’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $420,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Pzena Investment Management LLC increased its stake in Fresenius Medical Care AG & Co. KGaA by 0.6% during the 1st quarter. Pzena Investment Management LLC now owns 15,377,090 shares of the company’s stock valued at $382,890,000 after purchasing an additional 94,065 shares in the last quarter. Millennium Management LLC increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 50.0% during the first quarter. Millennium Management LLC now owns 1,083,602 shares of the company’s stock worth $26,982,000 after acquiring an additional 361,364 shares in the last quarter. Todd Asset Management LLC bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the first quarter worth about $12,009,000. Northern Trust Corp raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 5.0% in the 1st quarter. Northern Trust Corp now owns 380,251 shares of the company’s stock worth $9,468,000 after acquiring an additional 18,061 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky bought a new position in Fresenius Medical Care AG & Co. KGaA in the 1st quarter valued at about $7,420,000. 8.37% of the stock is owned by institutional investors and hedge funds.

Fresenius Medical Care AG & Co. KGaA Stock Down 1.1%

FMS stock opened at $24.70 on Tuesday. The firm has a 50 day moving average of $25.52 and a 200-day moving average of $25.97. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $18.94 and a 12 month high of $30.46. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.08 and a current ratio of 1.44.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its earnings results on Tuesday, August 5th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.02. The business had revenue of $5.54 billion for the quarter, compared to analysts’ expectations of $5 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.39% and a return on equity of 6.75%. Equities analysts expect that Fresenius Medical Care AG & Co. KGaA will post 1.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on FMS. Wall Street Zen lowered Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “buy” rating in a report on Friday, September 5th. Zacks Research downgraded Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Monday, August 18th. Morgan Stanley reissued an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, August 12th. Finally, UBS Group reiterated a “sell” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, September 2nd. One equities research analyst has rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus target price of $27.80.

Fresenius Medical Care AG & Co. KGaA Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.